152923-56-3

Basic information

• Product Name: Dacliximab
• Synonyms: Dacliximab;Daclizumab;Zenapax;Ro 24-7375;Immunoglobulin G 1 (human-mouse monoclonal clone 1H4 gamma-chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer
• CAS NO: 152923-56-3
• Molecular Weight: 0
• Mol File: 152923-56-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Dacliximab(CAS DataBase Reference)
• NIST Chemistry Reference: Dacliximab(152923-56-3)
• EPA Substance Registry System: Dacliximab(152923-56-3)

Safety Data

• Hazardous Substances Data: 152923-56-3(Hazardous Substances Data)

Usage

Uses

Dacliximab is monoclonal antibody (immunosuppressant.

Brand name

Zenapax (Hoffmann- LaRoche).

Clinical Use

Molecularly, daclizumab (Zenapax, Chimeric) is an IgG1MAb that binds specifically to the α subunit of the IL-2 receptor(the complete, high-affinity activated IL-2 receptorconsists of interacting α, β, and γ subunits). IL-2 receptorsare expressed on the surfaces of activated lymphocytes,where they mediate lymphocyte clonal expansion and differentiation.Daclizumab is a chimeric protein (90% humanand 10% mouse) IgG1. The MAb targets only recently activatedT cells that have interacted with antigen and have developedfrom their naive form into their activated form. Itis at this time that the IL-2 receptors are expressed. Thehuman amino acid sequences of daclizumab derive fromconstant domains of human IgG, and the variable domainsare derived from the fused Eu myeloma antibody. Themurine sequences derive from CDRs of a mouse anti-IL2αantibody.The indications for daclizumab are prophylaxis of acuteorgan rejection in patients receiving renal transplants, aspart of an immunosuppressant regimen including cyclosporineand corticosteroids. The mechanism of action isthe same as that of basiliximab.

Drug interactions

Potentially hazardous interactions with other drugsAvoid live vaccines.

Metabolism

As an IgG1 monoclonal antibody, daclizumab is expected to undergo catabolism to peptides and amino acids in the same manner as endogenous IgG. Daclizumab is not expected to undergo metabolism by hepatic enzymes such as CYP isoenzymes.